2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE, CA
Amended material disclosure
Investor Presentation
Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Completes Acquisition of Mersana Therapeutics
NOVEMBER 2025 Acquisition, Investor Presentation
FY 2024
Q3
Q2
Q1
Amended Annual Report
FY 2023
Tender Offer Statement by Third Party
Solicitation/Recommendation Statement
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Third Party